Navigation Links
Study in the New England Journal of Medicine Shows Non-Surgical Treatment for Pre-Cancerous Condition of Esophagus is Effective and Reduces Risk for Cancer Development

Data show superiority of endoscopic ablation therapy using the HALO System for eradicating Barrett's esophagus in randomized, multicenter, sham controlled trial

SUNNYVALE, Calif., May 27 /PRNewswire/ -- Results from a clinical study published today in the New England Journal of Medicine reveal that ablative therapy using the HALO system (BARRX Medical, Inc.) is highly effective for complete eradication of a pre-cancerous condition of the esophagus called Barrett's esophagus afflicting more than 3.3 million Americans. Additionally, ablative therapy using the HALO system reduced the risk of progression to cancer in the highest risk cohort studied (compared to control) from 19.0% to 2.4%.

The study entitled "Radiofrequency Ablation in Barrett's Esophagus with Dysplasia" is authored by lead investigator Nicholas J. Shaheen, M.D., Associate Professor of Medicine and Epidemiology, The University of North Carolina in Chapel Hill.

"This is a well-designed trial conducted in a rigorous manner at 19 expert U.S. centers, each having experience in the management of Barrett's esophagus, dysplasia, and cancer," said Dr. Shaheen. "Our results reported in the Journal are very promising, demonstrating superiority of ablation therapy for eliminating Barrett's and dysplasia, as well as reducing the rate of disease progression to more severe forms of dysplasia and esophageal cancer. This and data from other recent trials may ultimately change the paradigm for how gastroenterologists manage their patients with this disease."

As a result of chronic injury from gastroesophageal reflux disease (GERD), the normal esophageal lining is replaced with abnormal cells (Barrett's tissue), predisposing the patient to a higher risk for developing cancer of the esophagus. Patients with Barrett's who develop cancer, typically do so through a series of steps, starting with early Barrett's, then low-grade dysplasia or high-grade dysplasia, and then finally cancer. The present study included patients with the later stages of low- and high-grade dysplasia.

Beginning in 2006, the AIM Dysplasia Trial enrolled 127 patients having a diagnosis of Barrett's esophagus with dysplasia, the most advanced stage of this condition. Patients were randomly assigned to receive either endoscopic ablation with the HALO system or a sham intervention (control, no treatment). Tissue samples (biopsies) were obtained from the esophagus at regular intervals for one year after enrollment to assess for the presence of early Barrett's, dysplasia, and esophageal cancer. Comparison of the biopsy results at one year served as the primary outcome for the trial. The study endpoints were the eradication of all early Barrett's and, separately, all dysplasia in each group, as well as occurrence of new esophageal cancers.

At one-year follow-up, patients treated with ablation had a significantly higher complete eradication rate for both early Barrett's and dysplasia as compared to the control group. More than three quarters of treated patients had no detectable Barrett's at the end of the treatment period, compared to sham patients where 98% had persistent disease. The overall rate of disease progression to more severe forms of dysplasia and cancer was significantly lower in the ablation treatment group (3.6%) as compared to the control group (16.3%). In the highest risk cohort (high-grade dysplasia), ablative therapy significantly reduced the risk of progression to cancer by nearly 90% compared to control (2.4% in treated patients versus 19.0% in untreated controls).

About BARRX Medical, Inc.

BARRX Medical, Inc. develops treatment solutions for Barrett's esophagus, a precancerous condition of the lining of the esophagus (swallowing tube) caused by gastroesophageal reflux disease, or GERD. Its main product, the HALO360 System, provides a uniform and controlled ablation effect, which removes the diseased tissue and allows regrowth of normal cells. In the largest clinical trial conducted and published to date (the AIM-II Trial), 98.4 percent of patients were Barrett's-free after two and a half years of follow-up. The HALO90 System is the company's second ablation product, which is mounted on the end of an endoscope and used to treat smaller, non-circumferential areas of disease.

Both HALO systems are cleared by the FDA for use in the U.S. and both have CE Mark for use in Europe. More than 30,000 procedures have been performed in over 280 hospitals around the world. Based in Sunnyvale, Calif., BARRX Medical, Inc. was founded in 2000 and is privately-held. Additional information is available at

About the New England Journal of Medicine

The New England Journal of Medicine (N Engl J Med or NEJM) is an English-language peer-reviewed medical journal published by the Massachusetts Medical Society. It is one of the most popular and widely read peer-reviewed general medical journals in the world. It is also the oldest continuously published medical journal in the world. The journal usually has the highest impact factor of all journals of clinical medicine; in 2006, the impact factor was 51, according to Journal Citation Reports, the first research journal to break 50.

SOURCE BARRX Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Theranostics Health Announces Involvement with Major Academic Medical Center in Study Funded by Susan G. Komen for the Cure(R)
2. New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal
3. New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)
4. Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents
5. New NIH-Funded Study Shows Masimo Rainbow SET(R) May Help Clinicians Assess Oxygenation in Children With Sickle Cell Disease
6. Study Confirms Effectiveness of Innovative Prism Glasses For Hemianopia Patients
7. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
8. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
9. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
10. VIDEO from Medialink and the Epilepsy Foundation: New Study Suggests Different Versions of the Same Epilepsy Medication Can Be Harmful
11. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
Post Your Comments:
(Date:11/30/2015)... REHOVOT, Israel , Nov. 30, 2015 ... focused on acquiring and developing innovative therapies for ear, ... of Keith A. Katkin as chairman of ... Flesher , chief executive officer for OticPharma, Ltd.  "Keith ... As chairman, he will be able to share this ...
(Date:11/29/2015)...  Strengthening its leadership in connected healthcare informatics, ... IntelliSpace Portal 8.0 , the latest edition of ... helps radiologists detect, diagnose and follow-up on treatment of ... North America Annual Meeting (RSNA) in ... the changing demands in radiology that result from an ...
(Date:11/29/2015)... GE Health Cloud 1 was unveiled today at the ... America (RSNA) meeting in Chicago ... ecosystem and its applications will connect radiologists and clinicians to ... – both inside and outside the hospital setting. ... the digital industrial leader, we are betting big on the ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Newly reviewed and approved “NJ ... graduated from Tufts School of Dental Medicine in 1935. His father graduated from ... family being in dentistry as well as their commitment and passion to the Practice ...
(Date:11/30/2015)... ... November 30, 2015 , ... The ... National Poison Data System (NPDS) reveals that in 2014, someone called a poison ... over two million of which were human exposure cases. , The American Association ...
(Date:11/30/2015)... ... , ... Two years ago, Debbie Gregory, the CEO of, found herself ... Meditation (TM). After encouraging a number of veterans to go through the program, ... the talk. , TM is becoming one of the best alternative treatments for Post-Traumatic ...
(Date:11/30/2015)... ... ... The American Society for Clinical Pathology (ASCP) announced today that it has launched ... ASCP shared its “Give a minute. Get tested. Find a cure.” icon and infographic ... tested for HIV. , ASCP has asked members to replace their Facebook, Twitter, or ...
(Date:11/30/2015)... Beach, FL (PRWEB) , ... November 30, 2015 ... ... of Consumer Reports magazine, quoted Michael Hansen, Ph.D., a senior scientist at Consumer ... and even more so for a child’s exposure limits. , The original Nov ...
Breaking Medicine News(10 mins):